Abstract
O6-alkylguanine-DNA-alkyltransferase (ATase) activity was measured in extracts of peripheral blood mononuclear cells (PMCs) taken from eight patients at various times during 5 days of oral treatment with temozolomide (150 mg m-2, days 1-5). Pretreatment ATase levels ranged from approximately 70 to 600 fmol per mg of protein. Depletion of PMC ATase was seen within 4 h of the first dose of temozolomide and had a median nadir of 52.9% and values ranging from 44.4% to 71.0% of pretreatment levels. There was a correlation between the extent of ATase depletion (pretreatment minus nadir level) and the pretreatment ATase level (r = 0.97). A progressive depletion of ATase was observed during the 5 days of continuous temozolomide therapy with median ATase activities of 66.3%, 52.5%, 39.5%, 30.5% and 28.9% of the pretreatment values at days 2, 3, 4, 5 and 6 respectively. This suggests that the schedule-dependent anti-tumour activity of temozolomide seen in experimental models and clinics may be related to a cumulative depletion of ATase.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 24 print issues and online access
$259.00 per year
only $10.79 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Lee, S., Thatcher, N., Crowther, D. et al. Inactivation of O6-alkylguanine-DNA alkyltransferase in human peripheral blood mononuclear cells by temozolomide. Br J Cancer 69, 452–456 (1994). https://doi.org/10.1038/bjc.1994.82
Issue Date:
DOI: https://doi.org/10.1038/bjc.1994.82
This article is cited by
-
OIP5 Expression Sensitize Glioblastoma Cells to Lomustine Treatment
Journal of Molecular Neuroscience (2018)
-
Efficacy of protracted dose-dense temozolomide in patients with recurrent high-grade glioma
Journal of Neuro-Oncology (2011)
-
Continuous low-dose temozolomide and celecoxib in recurrent glioblastoma
Journal of Neuro-Oncology (2010)
-
Extended-schedule dose-dense temozolomide in refractory gliomas
Journal of Neuro-Oncology (2010)
-
O6-methylguanine-DNA methyltransferase depletion and DNA damage in patients with melanoma treated with temozolomide alone or with lomeguatrib
British Journal of Cancer (2009)